Devyser Diagnostics

Devyser Diagnostics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Devyser Diagnostics (DVYSR.ST) as of Oct 21, 2026 is 245.61. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -13.12 — a change of -1,971.63% (higher).

EV/FCF

245.61

YoY

-1,971.63%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Devyser Diagnostics is 2025 245.61 . EV/FCF (Enterprise Value to Free Cash Flow) of Devyser Diagnostics was 2024 -13.12 . It decreases by -1,971.63% higher compared to the previous year.

The Devyser Diagnostics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
1,787.72 SEK
Jan 1, 2019
323.77 SEK
Jan 1, 2020
-617.80 SEK
Jan 1, 2021
-53.16 SEK
Jan 1, 2022
-20.61 SEK
Jan 1, 2023
-14.95 SEK
Jan 1, 2024
-13.12 SEK
Jan 1, 2025
245.61 SEK
The Devyser Diagnostics EV/FCF history
YEAREV/FCFYoY
245.61-1,971.63%
-13.12-12.23%
-14.95-27.45%
-20.61-61.24%
-53.16-91.40%
-617.80-290.81%
323.77-81.89%
1,787.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Devyser Diagnostics is 245.61 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Devyser Diagnostics changed from -13.12 to 245.61, representing a -1,971.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Devyser Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics